Health Enhancement Products Inc. (HEPI) is pleased to announce that Scott Freeman, MD, has joined the company as Chief Science Officer.
Dr. Freeman will oversee planning, supervising and reviewing all clinical trials, isolation and characterization of the company’s algae-derived bioactives, validation methodologies, product platform development, and working with outside scientific consultants and researchers under contract to HEPI, including bio-pharmacologists, analytical chemists, food scientists, and physiologists, among others.
Dr. Freeman’s background includes experience in Medical Review Boards (MRB), Clinical Development Plan (CDP), FDA Regulatory Strategy, Drug Approvals, Translational Strategy, Biomarker Development, and Clinical Operations, including four years as Guest Researcher at the U.S. National Institutes of Health. He holds several patents relating to tumor and cancer treatment. Dr. Freeman received his medical degree from the University of Nevada and undergraduate degree from the University of Colorado.
Andrew Dahl, HEPI CEO, said: “As we continue to develop scientific support for our portfolio of bioactive compounds, Scott’s experience will insure that our licensing partners have ample support for their regulatory and marketing needs.”
About Health Enhancement Products Inc.
Health Enhancement Products Inc. is a health and wellness company engaged in the development of natural products derived from algae cultures for use as dietary supplements and food ingredients. The company has developed a portfolio of natural bioactive compounds wholly owned by Health Enhancement Products, protected by patents, patents pending and trade secrets, which are licensed to manufacturers. These natural products are extracted from living algae grown in purified water.